Bioactive Molecules against Rheumatoid Arthritis by Suppressing Pyroptosis
-
Published:2023-07-03
Issue:7
Volume:16
Page:952
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Zhou Qian1, Li Tian2, Fang Gang3, Pang Yuzhou1, Wang Xueni1ORCID
Affiliation:
1. Guangxi Zhuang Yao Medicine Center of Engineering and Technology, Guangxi University of Chinese Medicine, 13 Wuhe Road, Qingxiu District, Nanning 530200, China 2. School of Basic Medical Science, Guangxi University of Chinese Medicine, 13 Wuhe Road, Qingxiu District, Nanning 530200, China 3. School of Zhuang Medicine, Guangxi University of Chinese Medicine, 179 Mingxiudong Road, Xixiangtang District, Nanning 530001, China
Abstract
Rheumatoid arthritis is an inflammatory disease, and pyroptosis is a form of death associated with an inflammatory response. Pyroptosis, which occurs in synovial and osteoblastic cells, can exacerbate the development of rheumatoid arthritis. The inhibition of pyroptosis of these cells can, therefore, clearly be used as a therapeutic strategy against rheumatoid arthritis. Here, we have summarized the current status of progress in the treatment of rheumatoid arthritis by targeting cellular pyroptosis. We have identified seven compounds, including a cyclic RNA, a microRNA, a peptide, and a cytokine (protein), that may influence the progression of rheumatoid arthritis by regulating the initiation of pyroptosis. All of these compounds have been shown to have anti-rheumatoid effects in vitro and/or in vivo and have the potential to be developed as anti-rheumatoid agents. These findings may help to accelerate the development of anti-rheumatoid arthritis drugs.
Funder
National Natural Science Foundation of China Initial Scientific Research Fund of Guangxi University of Chinese Medicine Opening Foundation of Guangxi Key Laboratory of Chinese Medicine Foundation Research Development Program of High-Level Talent Team under Qihuang Project of Guangxi University of Chinese Medicine
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference80 articles.
1. Tanase, D.M., Gosav, E.M., Petrov, D., Teodorescu, D.-S., Buliga-Finis, O.N., Ouatu, A., Tudorancea, I., Rezus, E., and Rezus, C. (2022). MicroRNAs (miRNAs) in Cardiovascular Complications of Rheumatoid Arthritis (RA): What Is New?. Int. J. Mol. Sci., 23. 2. Airway Disease in Rheumatoid Arthritis;Matson;Ann. Am. Thorac. Soc.,2022 3. A Roadmap for Investigating Preclinical Autoimmunity Using Patient-Oriented and Epidemiologic Study Designs: Example of Rheumatoid Arthritis;Kowalski;Front. Immunol.,2022 4. Florescu, A., Gherghina, F.L., Musetescu, A.E., Padureanu, V., Rosu, A., Florescu, M.M., Criveanu, C., Florescu, L.-M., and Bobirca, A. (2022). Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease-A Narrative Review. Biomedicines, 10. 5. Mechanistic and therapeutic links between rheumatoid arthritis and diabetes mellitus;Li;Clin. Exp. Med.,2022
|
|